Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Daiichi starts Phase III HEART-FID trial of iron therapy for heart failure

American Regent Inc. began the Phase III HEART-FID trial of ferric carboxymaltose (Z-213) to treat heart failure with iron deficiency and reduced ejection

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE